Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$156 Mln
P/E Ratio
--
P/B Ratio
65.02
Industry P/E
--
Debt to Equity
-0.77
ROE
-1.99 %
ROCE
-401.72 %
Div. Yield
0 %
Book Value
--
EPS
-1.45
CFO
€-238.85 Mln
EBITDA
€-293.05 Mln
Net Profit
€-332.76 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
| 9.76 | -13.65 | -8.70 | -46.61 | -20.62 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Nanobiotix (NBTX)
| -60.28 | 98.37 | -54.69 | -50.91 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline... hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. Read more
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
Headquarters
Paris
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nanobiotix (NBTX) stood at $ 67 Mln as on 31-Dec-24
The share price of Nanobiotix (NBTX) is $3.15 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Nanobiotix (NBTX) has given a return of -20.62% in the last 3 years.
Nanobiotix (NBTX) has a market capitalisation of $ 156 Mln as on 25-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Nanobiotix (NBTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nanobiotix (NBTX) and enter the required number of quantities and click on buy to purchase the shares of Nanobiotix (NBTX).
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
The CEO & director of Mr. Laurent Levy Ph.D.. is Nanobiotix (NBTX), and CFO & Sr. VP is Mr. Laurent Levy Ph.D..
There is no promoter pledging in Nanobiotix (NBTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Nanobiotix (NBTX) | Ratios |
|---|---|
|
Return on equity(%)
|
201.73
|
|
Operating margin(%)
|
516.37
|
|
Net Margin(%)
|
586.89
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nanobiotix (NBTX) was No Profit.
$-0.15
(
